Goldman Sachs Initiates Coverage On Immunovant with Buy Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and a price target of $50.

March 13, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs initiated coverage on Immunovant with a Buy rating and set a price target of $50.
The initiation of coverage by a major financial institution like Goldman Sachs, especially with a Buy rating and a significant price target, is likely to generate positive sentiment among investors. This could lead to increased demand for IMVT shares in the short term, potentially driving up the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100